Form 8-K - Current report:
SEC Accession No. 0001731122-24-001896
Filing Date
2024-11-26
Accepted
2024-11-26 17:01:27
Documents
13
Period of Report
2024-11-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6171_8k.htm   iXBRL 8-K 29417
  Complete submission text file 0001731122-24-001896.txt   206643

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vrpx-20241125.xsd EX-101.SCH 3027
3 XBRL LABEL FILE vrpx-20241125_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vrpx-20241125_pre.xml EX-101.PRE 24173
15 EXTRACTED XBRL INSTANCE DOCUMENT e6171_8k_htm.xml XML 3806
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

EIN.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241505120
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)